...Thank you, Levay, and thanks to all of you who are joining our CEO, Dr. Shai Gozani; and myself for today's Q1 2023 earnings call. By way of background, we're a medtech company. Our mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health. Our commercial products are noninvasive. They address worldwide market opportunities, and they have no direct competition. Our neurodiagnostics, our DPNCheck and ADVANCE, and our neurotherapeutics are the Quell product line. Our business model is razor-razorblade. Aftermarket revenue is a principal component of product line profitability. Our strategic focus is to expand DPNCheck in the Medicare Advantage area and the Asian markets and to develop the Quell portfolio for specific disease indications. Earlier this morning, we reported Q1 revenue of $1.7 million, down 25% from $2.3 million in Q1 of last year. Within that decline, DPNCheck revenue was down 20% year-on-year. Domestic Medicare Advantage...
